Budget impact analysis of switch to darunavir/ritonavir monotherapy in Greece

Background: In virologically suppressed patients, simplifying to darunavir/ ritonavir (DRV/r) monotherapy maintains HIV RNA suppression and could lower treatment costs. Monotherapy is mentioned as an alternative treatment option in the Greek therapeutic guidelines (posted in the Greek Health Authority website), even though it is not included in the label of darunavir or any other PI. Methods: In the MONET trial 256 patients with HIV RNA